trovafloxacin has been researched along with piperacillin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 2 |
| Erwin, ME; Jones, RN; Worth, S | 1 |
| Falagas, ME; McDermott, L; Snydman, DR | 1 |
| Burgess, DS; Hastings, RW | 1 |
| Bonapace, CR; Bosso, JA; Friedrich, LV; White, RL | 1 |
1 review(s) available for trovafloxacin and piperacillin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for trovafloxacin and piperacillin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Cefoxitin; Ciprofloxacin; Fluoroquinolones; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperazines; Quinolones; Tazobactam | 1994 |
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical
Topics: Acetamides; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Azithromycin; Clavulanic Acids; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Naphthyridines; Oxazoles; Oxazolidinones; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality Control; Roxithromycin; Ticarcillin | 1996 |
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Topics: Anti-Infective Agents; Bacteroides; Bacteroides fragilis; Cefoxitin; Ciprofloxacin; Clostridium perfringens; Fluoroquinolones; Fusobacterium; Gram-Negative Anaerobic Bacteria; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Peptostreptococcus; Piperacillin; Prevotella melaninogenica; Quinolones; Tazobactam | 1997 |
Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Clindamycin; Drug Therapy, Combination; Fluoroquinolones; Hydrogen-Ion Concentration; Imipenem; Meropenem; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 1997 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Naphthyridines; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2000 |
Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Penicillins; Piperacillin; Reproducibility of Results; Tobramycin | 2000 |